Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Natalia RompotiIrene StefanakiPantelis PanagakisMarina PapoutsakiMaria PolitouCharitomeni VavouliAngeliki BefonFiori KoustaEleni LazouMaria ZaimiIoannis-Alexios KoumprentziotisVasiliki ChasapiDimitrios RigopoulosAlexander StratigosElectra NicolaidouPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)